TerminatedNCT00412620
Safety study of Safety and Efficacy of ABT-925 in schizophrenia
Researchers are comparing ABT-925 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are comparing ABT-925 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Anaheim and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateDecember 2006
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 156
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Argentina, Mexico
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00412620
- Official title
Show the full official title
Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Anaheim, United States · Cerritos, United States · Garden Grove, United States
13 more locations
- Pico Rivera, United States
- San Diego, United States
- Upland, United States
- North Miami, United States
- Atlanta, United States
- Austin, United States
- Bellaire, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Guadalajara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing ABT-925 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Abbott.
Does this study involve medication?
Yes. The study involves medication, including ABT-925 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)